In vitro, PD-1 blockade was shown to improve the ability of NK cells from Hodgkin lymphoma patients to mediate direct killing and ADCC against the PD-L1-expressing cell line HDLM2 [85]. Here, PDCD1 is linked to Hodgkins lymphoma.